chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Asymptomatic COVID-19, Biopsy lung abnormal, Blood alkaline phosphatase increased, Blood creatinine increased
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Blood urea increased, Chronic kidney disease, Computerised tomogram thorax abnormal, Condition aggravated, Decreased appetite
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Hypertension, Hypertransaminasaemia, Hypophagia, Inappropriate schedule of product administration
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Insomnia, Lung disorder, Pneumonitis, Prohormone brain natriuretic peptide increased, Pulmonary artery thrombosis
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Pulmonary embolism, Pulmonary fibrosis, Pulmonary mass, Pulmonary necrosis, SARS-CoV-2 test positive
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Sputum culture positive, Weight decreased
Clinical narrative: Pfizer Dose 1 9/12/21 (lot NA) Pfizer Dose 2 10/29/21 (301308A) COVID Positive 1/17/22  1/24/22: Patient is a 69 male who presented to ED with a chief complaint of generalized weakness.  Patient tested positive for COVID-19 on 01/17.  He has been fully vaccinated against COVID-19 but has not received his booster. He reports insomnia for the past week. Ongoing decreased appetite and oral intake. He has a past medical history of COPD chronically on 2 L NC, anxiety, hypertension, chronic pain, and former tobacco user. He has a LUL cavitary lung nodule that was discovered back in July. He has had multiple hospitalizations since. CT guided biopsy on 11/5 showed necrosis and reactive fibrosis, acute on chronic inflammation but no malignancy.  Sputum cultures on 10/23, 11/4 and 11/6 were positive for aspergillus and the patient was treated with Zosyn, vancomycin and micafungin. He reports significant weight loss over the past months, approximately 40 lb. He has decreased appetite and oral intake. No recent fevers, nausea, vomiting or diarrhea.  He was seen at HC on 1/13, advised to stop IV antibacterials and consider low dose azithromycin and repeating imaging in a few months, if no improvement repeat biopsy. Additional recommendations were to collect more sputa for AFB to exclude missed NTM and repeat blood work for histo AG, galactomannan, and fungal antibodies.   On arrival to ED patient was hypertensive 151/90. Laboratory findings were significant for CKD stage G 3A BUN 39 and creatinine 1.51.  Transaminitis AST 52 in ALP 252. ProBNP 1393. CT chest small thrombus in left upper lobe pulmonary artery.  Slightly increased size of the back wall cavitary lesion in the left upper lobe, most suggestive of aspergilloma.  New multifocal airspace disease most prominent in the lung periphery.  1/28/22: Patient was admitted for shortness of breath, CT pulmonary angiogram showed small PE, also has changes consistent with aspergilloma from before.  Patient was started on anticoagulation with Eliquis.  Patient was hemodynamically stable.  Also patient was diagnosed with COVID before.  Patient was asymptomatic from COVID. Patient was seen by Pulmonary and Infectious Disease specialist. Advised to continue with micafungin till May 22nd as prescribed.  Patient remained hemodynamically stable.  Patient continued on micafungin. On Eliquis which patient is tolerating well.  Patient discharged home today.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Apnoea, Cardiac arrest, Cardio-respiratory arrest, Death, Endotracheal intubation
Clinical narrative: Patient died on 6/24/2022 On June 24th, she was noted to become hypothermic.  She said that she was not feeling well, but did not give any focal symptoms.  She suddenly decompensated from a clinical standpoint and Code Blue was called.  She was found unresponsive, apneic, and pulseless.  CPR was performed.  Return of spontaneous circulation was achieved after 4 minutes.  She was given IV fluid and pressors were started.  She then went into another PEA arrest.  Return of spontaneous circulation was again achieved after about 4 minutes.  She did require intubation.  Workup revealed a market increase in her white blood cell count as well as drop in her hematocrit.  No obvious GI bleeding was noted.  There was also no obvious abdominal stigmata of intraabdominal bleeding.  Family requested DNR status.  She was given IV fluids and empiric antibiotics.  Stress dose steroids were added.  She was maintained on mechanical ventilatory support.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: General physical health deterioration, Haematocrit decreased, Hypothermia, Malaise, Mechanical ventilation
Clinical narrative: Patient died on 6/24/2022 On June 24th, she was noted to become hypothermic.  She said that she was not feeling well, but did not give any focal symptoms.  She suddenly decompensated from a clinical standpoint and Code Blue was called.  She was found unresponsive, apneic, and pulseless.  CPR was performed.  Return of spontaneous circulation was achieved after 4 minutes.  She was given IV fluid and pressors were started.  She then went into another PEA arrest.  Return of spontaneous circulation was again achieved after about 4 minutes.  She did require intubation.  Workup revealed a market increase in her white blood cell count as well as drop in her hematocrit.  No obvious GI bleeding was noted.  There was also no obvious abdominal stigmata of intraabdominal bleeding.  Family requested DNR status.  She was given IV fluids and empiric antibiotics.  Stress dose steroids were added.  She was maintained on mechanical ventilatory support.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Pulse absent, Pulseless electrical activity, Resuscitation, Unresponsive to stimuli, White blood cell count increased
Clinical narrative: Patient died on 6/24/2022 On June 24th, she was noted to become hypothermic.  She said that she was not feeling well, but did not give any focal symptoms.  She suddenly decompensated from a clinical standpoint and Code Blue was called.  She was found unresponsive, apneic, and pulseless.  CPR was performed.  Return of spontaneous circulation was achieved after 4 minutes.  She was given IV fluid and pressors were started.  She then went into another PEA arrest.  Return of spontaneous circulation was again achieved after about 4 minutes.  She did require intubation.  Workup revealed a market increase in her white blood cell count as well as drop in her hematocrit.  No obvious GI bleeding was noted.  There was also no obvious abdominal stigmata of intraabdominal bleeding.  Family requested DNR status.  She was given IV fluids and empiric antibiotics.  Stress dose steroids were added.  She was maintained on mechanical ventilatory support.
Age: 81.0
Sex: F
Vaccine: UNK
Symptoms: Pain in extremity
Clinical narrative: "This is a  81 Years  old  Female  presenting with pain to the right upper extremity that occurred three days ago.  Symptoms occurred gradually and are still present after receiving shingles vaccine.  Symptoms are described as moderate in nature. "
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Nausea
Clinical narrative: 101.5 Fever, chills, nausea, vomiting, dizziness, headache, exhaustion/fatigue,
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vomiting
Clinical narrative: 101.5 Fever, chills, nausea, vomiting, dizziness, headache, exhaustion/fatigue,
Age: 12.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Back pain, Central nervous system inflammation, Demyelination, Gait inability, Hypoaesthesia
Clinical narrative: Abnormal lesion in conus.  Competitive gymnast, no significant medical history. Developed constant bilateral low back pain. X-ray, MRI in August 2021, and PT, no significant improvement. January 2022 one night developed severe back pain and a sense of numbness and tingling, leg weakness, and could not walk.  Urinary incontinence. Prednisone 20 mg. daily for 6 days.  LS spine 2022 MRI lumbar spine demonstrates new abnormal signal within conus medullaris slightly greater within left hemicord. No definite mass thickening . Contrast MRI 1/31/22 Inflammatory demyelinating involving the conus medullaris and associated reactive inflammation of the ventral cauda equina nerve.  MRI February 2022 Brain no evidence of acute infarcation, C-spine no abnormal cord signal. Secon opiion Dr. at hospital, No evidence of MS. Back pain continues and competitive gymnastic career handicap persists with lower back pain and inability to fulfill skills. Scratching our heads!
Age: 12.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Impaired work ability, Magnetic resonance imaging, Magnetic resonance imaging head normal, Magnetic resonance imaging spinal abnormal, Muscular weakness
Clinical narrative: Abnormal lesion in conus.  Competitive gymnast, no significant medical history. Developed constant bilateral low back pain. X-ray, MRI in August 2021, and PT, no significant improvement. January 2022 one night developed severe back pain and a sense of numbness and tingling, leg weakness, and could not walk.  Urinary incontinence. Prednisone 20 mg. daily for 6 days.  LS spine 2022 MRI lumbar spine demonstrates new abnormal signal within conus medullaris slightly greater within left hemicord. No definite mass thickening . Contrast MRI 1/31/22 Inflammatory demyelinating involving the conus medullaris and associated reactive inflammation of the ventral cauda equina nerve.  MRI February 2022 Brain no evidence of acute infarcation, C-spine no abnormal cord signal. Secon opiion Dr. at hospital, No evidence of MS. Back pain continues and competitive gymnastic career handicap persists with lower back pain and inability to fulfill skills. Scratching our heads!
Age: 12.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Nervous system disorder, Paraesthesia, Scan with contrast abnormal, Urinary incontinence, X-ray
Clinical narrative: Abnormal lesion in conus.  Competitive gymnast, no significant medical history. Developed constant bilateral low back pain. X-ray, MRI in August 2021, and PT, no significant improvement. January 2022 one night developed severe back pain and a sense of numbness and tingling, leg weakness, and could not walk.  Urinary incontinence. Prednisone 20 mg. daily for 6 days.  LS spine 2022 MRI lumbar spine demonstrates new abnormal signal within conus medullaris slightly greater within left hemicord. No definite mass thickening . Contrast MRI 1/31/22 Inflammatory demyelinating involving the conus medullaris and associated reactive inflammation of the ventral cauda equina nerve.  MRI February 2022 Brain no evidence of acute infarcation, C-spine no abnormal cord signal. Secon opiion Dr. at hospital, No evidence of MS. Back pain continues and competitive gymnastic career handicap persists with lower back pain and inability to fulfill skills. Scratching our heads!
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Bundle branch block right, COVID-19 pneumonia, Cardiac arrest, Cardiomegaly, Chest X-ray abnormal
Clinical narrative: Patient with extensive PMH, with recent hospital admission for COVID PNA, reports back to Medical Center on 05/22/2022 with c/o SOB.  In the ED she was placed on BiPAP and given Lasix.  Portable chest xray demonstrated prior median sternotomy and left rib fixation.  Cardiac silhouette remained moderately enlarged, diffuse pulmonary vascular engorgement with bilateral mixed interstitial and alveolar infiltrates, favoring pulmonary edema as an etiology.  ECG revealed prior inferior infarct, RBBB.  She was admitted to the hospital and transferred to ICU where she required intubation.  On 5/28/2022 patient had cardiac arrest, started on amiodarone.  06/01/2022 family in agreement with DNR status, and patient expired on 06/03/2022.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Death, Dyspnoea, Electrocardiogram abnormal, Endotracheal intubation, Intensive care
Clinical narrative: Patient with extensive PMH, with recent hospital admission for COVID PNA, reports back to Medical Center on 05/22/2022 with c/o SOB.  In the ED she was placed on BiPAP and given Lasix.  Portable chest xray demonstrated prior median sternotomy and left rib fixation.  Cardiac silhouette remained moderately enlarged, diffuse pulmonary vascular engorgement with bilateral mixed interstitial and alveolar infiltrates, favoring pulmonary edema as an etiology.  ECG revealed prior inferior infarct, RBBB.  She was admitted to the hospital and transferred to ICU where she required intubation.  On 5/28/2022 patient had cardiac arrest, started on amiodarone.  06/01/2022 family in agreement with DNR status, and patient expired on 06/03/2022.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Lung disorder, Lung infiltration, Myocardial infarction, Positive airway pressure therapy, Sternotomy
Clinical narrative: Patient with extensive PMH, with recent hospital admission for COVID PNA, reports back to Medical Center on 05/22/2022 with c/o SOB.  In the ED she was placed on BiPAP and given Lasix.  Portable chest xray demonstrated prior median sternotomy and left rib fixation.  Cardiac silhouette remained moderately enlarged, diffuse pulmonary vascular engorgement with bilateral mixed interstitial and alveolar infiltrates, favoring pulmonary edema as an etiology.  ECG revealed prior inferior infarct, RBBB.  She was admitted to the hospital and transferred to ICU where she required intubation.  On 5/28/2022 patient had cardiac arrest, started on amiodarone.  06/01/2022 family in agreement with DNR status, and patient expired on 06/03/2022.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Surgical fixation of rib fracture
Clinical narrative: Patient with extensive PMH, with recent hospital admission for COVID PNA, reports back to Medical Center on 05/22/2022 with c/o SOB.  In the ED she was placed on BiPAP and given Lasix.  Portable chest xray demonstrated prior median sternotomy and left rib fixation.  Cardiac silhouette remained moderately enlarged, diffuse pulmonary vascular engorgement with bilateral mixed interstitial and alveolar infiltrates, favoring pulmonary edema as an etiology.  ECG revealed prior inferior infarct, RBBB.  She was admitted to the hospital and transferred to ICU where she required intubation.  On 5/28/2022 patient had cardiac arrest, started on amiodarone.  06/01/2022 family in agreement with DNR status, and patient expired on 06/03/2022.
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Mental status changes, SARS-CoV-2 test positive, Unresponsive to stimuli
Clinical narrative: Pfizer Dose 1 1/14/21 (lot NA) Pfizer Dose 2 2/4/21 (lot NA) Pfizer Dose 3 10/26/21 (FF2593) COVID Positive 3/1/22  3/1/22: Patient is a 94-year-old male history of chronic underlying dementia presents to ER via EMS from facility for altered mental status that is characterized as unresponsiveness.  History today is very limited majority was obtained from ER physician, per ER provider report patient tested positive for COVID-19 on February 28, family was updated regarding patient's condition in ER requested for comfort care.  Patient is DNR/DNI.  3/2/22: Patient is admitted hospital, continued on comfort measures.  Hospice consult is requested, patient is evaluated by hospice team, and is discharged back to Facility with hospice.
Age: 45.0
Sex: M
Vaccine: PNC20
Symptoms: Arthralgia, Chest pain, Injection site pain, Injection site swelling
Clinical narrative: Local site swelling and pain, chest pain and shoulder pain. Pt had to go to ER
Age: 68.0
Sex: F
Vaccine: COVID19, PNC13
Symptoms: COVID-19, Fatigue, Head discomfort, SARS-CoV-2 test positive, Throat irritation
Clinical narrative: It started on Friday with slight tickle and scratch in my throat with head congestion.  I felt really tired.  My asthma did not kick in.  The first three nights I took cold medicine and was able to sleep.  I started feeling better on the fourth day.  I tested negative with my home test on Saturday and retested Monday and was positive.  I was unable to get into the doctor.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza, Nasopharyngitis, SARS-CoV-2 test
Clinical narrative: Flu/cold/ allergy symptoms - home care liquids, rest, Aleve  and cold meds.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Asthenia, Blood gases abnormal, Breath sounds abnormal, COVID-19
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chills, Computerised tomogram thorax abnormal, Cough, Crepitations
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness postural, Dyspnoea, Dyspnoea exertional, Hypoxia, Inappropriate schedule of product administration
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Laboratory test abnormal, Leukopenia, Lung consolidation, Lung opacity, Metabolic acidosis
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Positive airway pressure therapy, Pyrexia, Respiratory acidosis, SARS-CoV-2 test positive
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Walking distance test abnormal, Wheezing
Clinical narrative: Pfizer Dose 1 9/25/21 (lot NA) Pfizer Dose 2 11/13/21 (lot NA) COVID Positive 1/18/22  1/18/22: The patient complaining from generalized weakness associated with shortness of breath with minimal exertion associated with dry cough and episodes of postural dizziness, no fever or chills or sore throat, no chest pain or palpitation or lower limb swelling.  She is vaccinated for COVID-19 and she did not get the booster.   She is a former smoker and currently vaping.  She is morbidly wheeze and she does not use CPAP at home and no official diagnosis of obstructive sleep apnea.   At emergency she was hypoxic requiring 12 L of oxygen   ABG show severe mixed respiratory and metabolic acidosis which improved after IV fluids, her labs show leukopenia  CT chest reviewed personally and show bilateral ground-glass opacity with focal consolidation  1/20/22: The patient known to be morbidly obese, vaccinated for COVID-19, presented with fever and chills and shortness of breath with cough and chest discomfort with nausea, she was hypoxic and require initially BiPAP, had bilateral wheezing and crepitation her chest exam with decreased air entry, her ABG show metabolic and respiratory acidosis, had chest CT angiogram negative for PE and show bilateral ground-glass opacity with focal linear consolidation, patient started on remdesivir and dexamethasone and antibiotics with CPAP hs with improvement in her respiratory status until she does not require oxygenation at rest.  Oxygen walking test completed and show the patient does not require oxygenation at rest and she require 3 L of oxygen while ambulating.  The patient will need to continue her medication, follow-up as an outpatient to schedule a sleep study follow-up with pulmonologist.  Counseled about losing weight and avoid vaping/smoking.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Cough, Hypophagia, Malaise
Clinical narrative: I started feeling ill on June 24, 2022, I could not eat or drink anything. I called to get in to an urgent care but could not get in Monday June 27, 2022 the rapid COVID-19 test came back positive but the also did a PCR COVID-19 test. I got a call on Tuesday June 28, 2022 that confirmed that the rapid test was correct. I have a sore throat and coughing, fever, chills. I have been advised to take vitamin D, C, and zinc to help boost my immune system.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: I started feeling ill on June 24, 2022, I could not eat or drink anything. I called to get in to an urgent care but could not get in Monday June 27, 2022 the rapid COVID-19 test came back positive but the also did a PCR COVID-19 test. I got a call on Tuesday June 28, 2022 that confirmed that the rapid test was correct. I have a sore throat and coughing, fever, chills. I have been advised to take vitamin D, C, and zinc to help boost my immune system.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: patient received expired medication. confirmed with manufacturer that dose maintained its efficacy. no follow-up needed. no adverse outcome
Age: 1.83
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Lethargy, Urticaria
Clinical narrative: After she received the vaccine she was lethargic and hardly had an appetite. She woke up the next day with hives on her foot and inner thigh. After 30 minutes they disappeared. Through out the course of the day hives were popping up on different places of her body. At 6:45PM I gave her some ZYRTEC. The next morning when she woke up the hives were gone. On June 29, 2022 I took her to the doctor. The doctor said that the hives could have been virally triggered or caused by the vaccine, and they recommended for her to not get the 2nd dose. The doctor said to see her allergist to see what they think. She also has no history of ever having hives before.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Anion gap, Anticoagulant therapy, Aspartate aminotransferase increased, Blood chloride decreased, Blood creatinine increased
Clinical narrative: Pfizer Dose 1 2/8/21 (EN6201) Pfizer Dose 2 3/1/21 (EN6203) COVID Positive 1/4/22  1/4/22: Patient is an 87-year-old male with past medical history significant for type 2 diabetes, CKD, CAD s/p stent placement, hypertension, B12 deficiency, history of unprovoked PE in 2018 currently anticoagulated on Eliquis, recent COVID-19 infection, melanoma with metastatic disease to lungs.  The patient presents to the ED today via EMS from a facility with worsening shortness of breath.  Of note, the patient was admitted to the Hospital for 3 weeks due to COVID-19 pneumonia, he was discharged to a facility 1/3/2022 on 8 L of oxygen via nasal cannula.  The patient's HPI is difficult to obtain due to his significant hypoxia and fatigue. The patient is not able to answer questions appropriately during examination.  Of note, the patient follows with Dr. for the management of his metastatic melanoma.  The patient had a CT of his chest completed on 11/30/2021 and reviewed slight enlargement of the pulmonary nodule in the right middle lobe.  He was previously being treated with keytruda; however, it has been on hold for 2 months due to worsening performance while on keytruda.   Upon arrival to the ED patient's temperature is 99.3°, heart rate 88, respirations 39, pulse ox 91% on 15 L high-flow oxygen, blood pressure 117/58.  The patient was subsequently placed on BiPAP at 50% FiO2 to maintain O2 saturations greater than 90%.  Patient's laboratory findings are significant for sodium 130, chloride 93, a gap 18, glucose 205, BUN 38, creatinine 1.68, AST 64, WBC 12.71, hemoglobin 11.5, hematocrit 36.1.  The patient received 6 mg IV Decadron, DuoNeb x1, Levaquin 750 mg IV, 2 L IV normal saline in ED.  1/6/22: Discontinue routine blood checks  Discontinue glucometer and insulin  Continue with comfort measures  Follow-up with care coordination and hospice team about DC to skilled on hospice Other medications discontinued.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose increased, Blood sodium decreased, Blood urea increased, COVID-19, COVID-19 pneumonia
Clinical narrative: Pfizer Dose 1 2/8/21 (EN6201) Pfizer Dose 2 3/1/21 (EN6203) COVID Positive 1/4/22  1/4/22: Patient is an 87-year-old male with past medical history significant for type 2 diabetes, CKD, CAD s/p stent placement, hypertension, B12 deficiency, history of unprovoked PE in 2018 currently anticoagulated on Eliquis, recent COVID-19 infection, melanoma with metastatic disease to lungs.  The patient presents to the ED today via EMS from a facility with worsening shortness of breath.  Of note, the patient was admitted to the Hospital for 3 weeks due to COVID-19 pneumonia, he was discharged to a facility 1/3/2022 on 8 L of oxygen via nasal cannula.  The patient's HPI is difficult to obtain due to his significant hypoxia and fatigue. The patient is not able to answer questions appropriately during examination.  Of note, the patient follows with Dr. for the management of his metastatic melanoma.  The patient had a CT of his chest completed on 11/30/2021 and reviewed slight enlargement of the pulmonary nodule in the right middle lobe.  He was previously being treated with keytruda; however, it has been on hold for 2 months due to worsening performance while on keytruda.   Upon arrival to the ED patient's temperature is 99.3°, heart rate 88, respirations 39, pulse ox 91% on 15 L high-flow oxygen, blood pressure 117/58.  The patient was subsequently placed on BiPAP at 50% FiO2 to maintain O2 saturations greater than 90%.  Patient's laboratory findings are significant for sodium 130, chloride 93, a gap 18, glucose 205, BUN 38, creatinine 1.68, AST 64, WBC 12.71, hemoglobin 11.5, hematocrit 36.1.  The patient received 6 mg IV Decadron, DuoNeb x1, Levaquin 750 mg IV, 2 L IV normal saline in ED.  1/6/22: Discontinue routine blood checks  Discontinue glucometer and insulin  Continue with comfort measures  Follow-up with care coordination and hospice team about DC to skilled on hospice Other medications discontinued.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram thorax abnormal, Dyspnoea, Fatigue, Haematocrit decreased, Haemoglobin decreased
Clinical narrative: Pfizer Dose 1 2/8/21 (EN6201) Pfizer Dose 2 3/1/21 (EN6203) COVID Positive 1/4/22  1/4/22: Patient is an 87-year-old male with past medical history significant for type 2 diabetes, CKD, CAD s/p stent placement, hypertension, B12 deficiency, history of unprovoked PE in 2018 currently anticoagulated on Eliquis, recent COVID-19 infection, melanoma with metastatic disease to lungs.  The patient presents to the ED today via EMS from a facility with worsening shortness of breath.  Of note, the patient was admitted to the Hospital for 3 weeks due to COVID-19 pneumonia, he was discharged to a facility 1/3/2022 on 8 L of oxygen via nasal cannula.  The patient's HPI is difficult to obtain due to his significant hypoxia and fatigue. The patient is not able to answer questions appropriately during examination.  Of note, the patient follows with Dr. for the management of his metastatic melanoma.  The patient had a CT of his chest completed on 11/30/2021 and reviewed slight enlargement of the pulmonary nodule in the right middle lobe.  He was previously being treated with keytruda; however, it has been on hold for 2 months due to worsening performance while on keytruda.   Upon arrival to the ED patient's temperature is 99.3°, heart rate 88, respirations 39, pulse ox 91% on 15 L high-flow oxygen, blood pressure 117/58.  The patient was subsequently placed on BiPAP at 50% FiO2 to maintain O2 saturations greater than 90%.  Patient's laboratory findings are significant for sodium 130, chloride 93, a gap 18, glucose 205, BUN 38, creatinine 1.68, AST 64, WBC 12.71, hemoglobin 11.5, hematocrit 36.1.  The patient received 6 mg IV Decadron, DuoNeb x1, Levaquin 750 mg IV, 2 L IV normal saline in ED.  1/6/22: Discontinue routine blood checks  Discontinue glucometer and insulin  Continue with comfort measures  Follow-up with care coordination and hospice team about DC to skilled on hospice Other medications discontinued.